DiscoverMPR Weekly DoseMPR Weekly Dose Podcast #256 — HRT Label Changes; Calypta Approved for MDD; Darzalex Faspro Indication Expanded; MS Tx Potential; Simplified HIV Regimen
MPR Weekly Dose Podcast #256 — HRT Label Changes; Calypta Approved for MDD; Darzalex Faspro Indication Expanded; MS Tx Potential; Simplified HIV Regimen

MPR Weekly Dose Podcast #256 — HRT Label Changes; Calypta Approved for MDD; Darzalex Faspro Indication Expanded; MS Tx Potential; Simplified HIV Regimen

Update: 2025-11-14
Share

Description

The FDA requests boxed warnings be removed from HRT product labels; Caplyta approved for MDD; Darzalex Faspro gains new indication; investigational MS treatment looks promising; trial investigates simplified HIV regimen.

Comments 
In Channel
loading
00:00
00:00
x

0.5x

0.8x

1.0x

1.25x

1.5x

2.0x

3.0x

Sleep Timer

Off

End of Episode

5 Minutes

10 Minutes

15 Minutes

30 Minutes

45 Minutes

60 Minutes

120 Minutes

MPR Weekly Dose Podcast #256 — HRT Label Changes; Calypta Approved for MDD; Darzalex Faspro Indication Expanded; MS Tx Potential; Simplified HIV Regimen

MPR Weekly Dose Podcast #256 — HRT Label Changes; Calypta Approved for MDD; Darzalex Faspro Indication Expanded; MS Tx Potential; Simplified HIV Regimen